In cost-saving move, Medicare could limit patient access to Alzheimer’s treatment
Medicare might restrict patient access to Alzheimer’s treatment priced at $ 56,000 for a year’s supply to soften the financial blow to the federal insurance program’s budget. “Whether or not that drug will be covered by Medicare and Medicaid is is an outstanding question, something that HHS will have to deal with,” said Health and… Read More »